Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New name for Oxford Genome Sciences

This article was originally published in Scrip

Executive Summary

Oxford Genome Sciences has changed its name to Oxford BioTherapeutics (OBT). OBT said the new name reflected the company's focus on the discovery and development of targeted antibody medicines to address large and unmet patient needs in oncology. The company is co-developing its lead programmes with Medarexon a 50:50 cost and profit share basis, and it is collaborating with other companies. The Medarex agreement, signed in May 2006, uses OBT's Oxford Genome Anatomy Project database to provide novel colorectal cancer targets, against which Medarex hopes to generate fully human monoclonal antibodies using its UltiMAb human antibody development system. The new name marks a key turning point in OBT's development, as it grows into an oncology-focused clinical development organisation, Dr Christian Rohlff, the company's CEO, said.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts